JNJ

Featured

Could Biotech ETFs Get Another Boost From JNJ News?

By Ian YoungAugust 26, 2021

Equity ETF Channel

Is it Time to Rotate to Health Care?

By Todd RosenbluthApril 30, 2021

Featured

Stock ETFs Score Fresh Highs Amid Bank Earnings

By Ian YoungApril 14, 2021

Equity ETF Channel

Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause

By Ian YoungApril 13, 2021

Featured

Stock ETFs Remain Mixed on Tuesday

By Ian YoungApril 13, 2021

Featured

J&J’s Vaccine Rollout a Shot in the Arm for These Biotech ETFs

By Ian YoungMarch 2, 2021

Featured

Biotech ETFs Pop Amid Pending J&J Vaccine Approval

By Ian YoungFebruary 24, 2021

Equity ETF Channel

A Popular Blue-Chip Focused ETF Remains Appealing

By Todd RosenbluthFebruary 2, 2021

Featured

Stock ETFs Consolidate on Stimulus Hopes and Unemployment Data

By Ian YoungJanuary 14, 2021

Nasdaq Investment Intelligence Channel

A Power Pharmaceuticals ETF to Consider

By Tom LydonJuly 27, 2020

Featured

QMJ: An ETF To Trade The Winners And The Losers

By Ian YoungJuly 15, 2020

Featured

Biotech ETFs Climbing As Moderna Builds Hope For Coronavirus Vaccine

By Ian YoungMay 18, 2020

Core Equity Channel

Stick With Royalty for Dividend Dependability

By Tom LydonMay 11, 2020

Featured

Abbott Labs Helps Boost Healthcare ETFs

By Ian YoungApril 16, 2020

Featured

Healthcare ETFs Hold Their Ground As Stocks Selloff On Poor Data Wednesday

By Ian YoungApril 15, 2020

Featured

Stocks And ETFs Struggle To Hold Recent Gains At End Of Quarter

By Ian YoungMarch 31, 2020

Core Equity Channel

An Aristocratic Dividend ETF Really Matters in These Wild Times

By Tom LydonMarch 31, 2020

Innovative ETFs Channel

3 Ways to Play the Healthcare Surge

By Special To ETF TrendsDecember 30, 2019